source
- CRISPR Therapeutics to test highest dose of lipid‑lowering gene editing therapy after mixed durability dataCRISPR Therapeutics presented early‑stage data at the European Society of Cardiology meeting showing that its lipid‑lowering gene editing candidate produced mixed durability results a year after pa…
- AstraZeneca and Ionis report unexpected failure of heart disease drug in trialAstraZeneca and Ionis disclosed that their collaborative heart disease drug did not meet primary endpoints in a recent trial, marking a surprise setback. The companies detailed the trial results,…